Jefferies London Healthcare Conference
CLINUVEL's Chief Executive Officer, Dr Philippe Wolgen, presents to the Jefferies Healthcare...
Read More
CLINUVEL Communiqué V
News Communiqué V discusses CLINUVEL's strong financial results in the face of...
Read More
Appendix 3Y - Change of Director’s Interest Notice
Melbourne, Australia, 07 November 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
Results of Annual General Meeting 2022
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read More
CLINUVEL Pharmaceuticals Investor Briefing Melbourne
CLINUVEL held an Investor Briefing in Melbourne, with a presentation by Managing...
Read More
First vitiligo patient enrolled in afamelanotide monotherapy study
CUV104 study to evaluate the role of afamelanotide as monotherapy in patients...
Read More
CLINUVEL PHARMACEUTICALS LTD Annual General Meeting - Notice of Meeting & Explanatory Memorandum 2022
CLINUVEL released the formal Notice of Meeting and Explanatory Memorandum for its...
Read More
Strategic Update V
CLINUVEL today announced its fifth Strategic Update, focused on the evolution and...
Read More
H.C. Wainwright 24th Annual Global Investment Conference
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read More
CLINUVEL confirms AGM date
CLINUVEL confirms the date for the Company’s 2022 Annual General Meeting.
Read More
CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients
European regulatory submission follows clinical support for SCENESSE® treatment in EPP patients...
Read More
CLINUVEL Kommuniqué IV
Seit dem letzten News Communiqué vom 23. Juni hat CLINUVEL die Entwicklung...
Read More